AbbVie Inc. $ABBV Shares Purchased by Ethos Financial Group LLC

Ethos Financial Group LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 3.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 11,693 shares of the company’s stock after buying an additional 387 shares during the period. Ethos Financial Group LLC’s holdings in AbbVie were worth $2,170,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. TD Capital Management LLC grew its holdings in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares during the period. Marshall & Sullivan Inc. WA purchased a new stake in shares of AbbVie during the 2nd quarter valued at $25,000. Cypress Capital Management LLC WY acquired a new stake in shares of AbbVie during the 1st quarter worth $35,000. Bear Mountain Capital Inc. increased its holdings in shares of AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares during the last quarter. Finally, Access Investment Management LLC purchased a new position in shares of AbbVie in the 2nd quarter worth $44,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

ABBV has been the topic of a number of research reports. Guggenheim raised their price objective on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Bank of America raised their price target on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Daiwa America upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 7th. UBS Group set a $251.00 target price on AbbVie in a research note on Friday, October 3rd. Finally, Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $238.05.

Insider Buying and Selling

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president owned 177,292 shares in the company, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.25% of the company’s stock.

AbbVie Trading Up 0.5%

Shares of NYSE:ABBV opened at $216.96 on Thursday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a market capitalization of $383.27 billion, a price-to-earnings ratio of 103.31, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 1-year low of $163.81 and a 1-year high of $244.81. The company has a 50 day moving average price of $222.84 and a 200 day moving average price of $201.84.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.